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Introduction: Circulating microRNAs (miRNAs) are easily accessible and have already proven to be useful as
prognostic markers in cancer patients. However, their origin and function in the circulation is still under discussion.
In the present study we analyzed changes in the miRNAs in blood plasma of head and neck squamous cell
carcinoma (HNSCC) patients in response to radiochemotherapy and compared them to the changes in a cell
culture model of primary HNSCC cells undergoing simulated anti-cancer therapy.
Materials and methods: MiRNA-profiles were analyzed by qRT-PCR arrays in paired blood plasma samples of HNSCC
patients before therapy and after two days of treatment. Candidate miRNAs were validated by single qRT-PCR assays.
An in vitro radiochemotherapy model using primary HNSCC cell cultures was established to test the possible tumor
origin of the circulating miRNAs. Microarray analysis was performed on primary HNSCC cell cultures followed by
validation of deregulated miRNAs via qRT-PCR.
Results: Unsupervised clustering of the expression profiles using the six most regulated miRNAs (miR-425-5p, miR-21-5p,
miR-106b-5p, miR-590-5p, miR-574-3p, miR-885-3p) significantly (p = 0.012) separated plasma samples collected prior to
treatment from plasma samples collected after two days of radiochemotherapy. MiRNA profiling of primary HNSCC cell
cultures treated in vitro with radiochemotherapy revealed differentially expressed miRNAs that were also observed to be
therapy-responsive in blood plasma of the patients (miR-425-5p, miR-21-5p, miR-106b-5p, miR-93-5p) and are therefore
likely to stem from the tumor. Of these candidate marker miRNAs we were able to validate by qRT-PCR a deregulation of
eight plasma miRNAs as well as miR-425-5p and miR-93-5p in primary HNSCC cultures after radiochemotherapy.
Conclusion: Changes in the abundance of circulating miRNAs during radiochemotherapy reflect the therapy response
of primary HNSCC cells after an in vitro treatment. Therefore, the responsive miRNAs (miR-425-5p, miR-93-5p) may
represent novel biomarkers for therapy monitoring. The prognostic value of this exciting observation requires
confirmation using an independent patient cohort that includes clinical follow-up data.
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Surgical treatment of head and neck squamous cell
carcinoma (HNSCC) is limited by the complex anat-
omy of the tumors and the associated risk of morbidity.
Hence, for many patients an alternative treatment
strategy of definitive radiotherapy alone or in conjunc-
tion with chemotherapy or immunotherapy is required
[1]. Despite considerable progress in treatment op-
tions, disease recurrence and metastasis with a very
strong impact on long-term survival are still the major
challenges [2].
MicroRNAs (miRNAs) are evolutionarily conserved
small RNAs, representing a class of regulators of post-
transcriptional gene expression. There are more than
2000 mature miRNAs currently annotated in the human
genome miRBase (release 19.0) [3] potentially targeting
over 60% of all proteins [4]. Fundamental cellular pro-
cesses including development, apoptosis [5], cell cycle
control, proliferation [6] and DNA-damage repair [7] are
influenced by miRNAs. During the last decade alterations
in miRNA expression have been associated with a number
of human diseases, including cancer (reviewed in [8]). The
recent discovery of miRNAs in body fluids such as cere-
brospinal fluid [9] and blood plasma [10] opens up the
possibility of using miRNAs as minimally invasive bio-
markers for the prediction of clinical endpoints such as
overall survival [11,12]. The well described ‘onco-miR’
miR-21 has already been identified as a valuable plasma
biomarker with high prognostic power in esophageal squa-
mous cell carcinoma [13] and gastric cancer [14].
Since the expression of miRNAs is known to be altered
by ionizing radiation at both the cellular level [15] and
plasma levels of mice [16], they might serve as easily ac-
cessible predictors of the individual response to radiation
therapy. Additionally, miRNAs regulate drug sensitivity
[17] and influence radioresistance [18-20]. This offers the
possibility of using specific plasma miRNAs as biomarkers
for optimized treatment decisions.
The present study aimed to identify blood plasma miR-
NAs showing a response to radiochemotherapy and further
to clarify the origin of these miRNAs in order to use them
as minimally invasive tools for therapy monitoring.
For this purpose we compared miRNA levels in sam-
ples of blood plasma from HNSCC patients prior to
treatment and after the completion of the first two
fractions of therapeutic irradiation. MiRNAs displaying
altered concentration levels after treatment were further
analyzed in peripheral blood mononuclear cells (PBMC)
of the same patients to test the hypothesis of PBMC-
derived alterations of the plasma miRNAs. Moreover, we
established an in vitro radiochemotherapy model using
primary HNSCC cells in order to investigate a potential
tumor origin of the therapy-responsive miRNAs in blood
plasma.Materials and methods
Patient samples
Plasma miRNA analysis was performed on 18 patients
(17 HNSCC, 1 esophageal adenocarcinoma) treated with
local X-ray-irradiation using a linear accelerator (6 MV,
Siemens Mevatron M or ELEKTA Synergy®). After a
planning (PET-) CT scan 70 Gy were applied to the
macroscopic tumor and involved lymph nodes in daily
dose fractions of 2 Gy five days per week. The adjuvant
lymphatics were irradiated with up to 50 Gy and the
high-risk lymphatics (adjacent to the involved lymph
node levels) with up to 60 Gy.
16 out of 18 patients received concurrent chemotherapy
(12 patients received 5-fluorouracil (5-FU) plus mitomycin
C (MMC) [21], 3 patients MMC and 1 patient cisplatin
weekly). None of the patients underwent surgical treat-
ment. 5-FU treatment was usually applied on each of the
first 5 days of therapeutic irradiation whereas MMC was
applied only on day 5 and day 36 during radiotherapy.
Patient characteristics are listed in Table 1.
After obtaining ethical approval and informed con-
sent, 15 ml of EDTA-peripheral blood were collected
from each patient prior to the first fraction of therapy
and within one hour after the second fraction of thera-
peutic irradiation. EDTA-blood samples were centri-
fuged at 350 × g for 10 min within two hours after
collection to obtain plasma. To avoid cellular contamin-
ation the plasma samples were re-centrifuged at 1,200 ×
g for 3 min and subsequently at 14,000 × g for 10 min to
remove cell debris.
PBMC were isolated using Ficoll gradient centrifugation.
Samples were stored at −20°C until further analysis or
at −80°C for long term storage.
The study was approved by the ethics committee of
the University of Munich (Germany).
Primary HNSCC cells
Primary tumor cells were obtained from the fresh tumor
biopsies of two HNSCC cases, HN1957 (left maxilla/left
nasal floor) and HN2092 (right floor of mouth) received
from the Wales Cancer Bank, UK [22]. The tumor tis-
sues were rinsed with PBS, minced and cultivated in
keratinocyte media supplemented with L-glutamine,
penicillin/streptomycin, EGF, BPE, CaCl2, F-12, DMEM
(all components: Life Technologies) and 10% FBS at
37°C and 5% CO2. To ensure the exclusive cultivation
of epithelial cells from tissue particles, fibroblast cells
were identified via frequent microscopy and removed
by scraping. The FBS-content of the media was con-
tinuously reduced down to serum-free cultivation. The
epithelial origin of both cultures was assessed by po-
sitive cytokeratin staining via immunohistochemistry
(Additional file 1). Characteristics of the two primary
HNSCC cultures are listed in Table 2.
Table 1 Patient characteristics




Median age, years 57.9

























(in addition to radiotherapy)
5-FU +MMC 12 (patient 3, 5–7,
9–13, 15–17)
MMC 3 (patient 1, 14, 18)
Cisplatin 1 (patient 8)
Cetuximab 1 (patient 4)





5-FU = 5-fluorouracil; MMC =mitomycin C;
n.a. = not available.
Table 2 Characteristics of primary HNSCC cell cultures
Characteristic HN1957 HN2092
Gender of patient female male
Age at diagnosis, years 85 73
Tumor site left maxilla/left nasal floor right floor of mouth
TNM n.a. pT4pN0
Cell type epithelial epithelial
n.a. = not available.
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To model as closely as possible the most frequent chemo-
therapy treatment we tested different 5-FU treatmentoptions using the primary HNSCC cultures. Cell viability
was measured using the XTT cell proliferation kit II
(Roche) for both cell cultures after applying a wide range
of 5-FU doses (Figure 1a, b). The 5-FU concentrations
were selected to be relatively high, however lying within
the linear region of the dose–response curve. Thus,
HN1957 cells were treated with 50 μM 5-FU and HN2092
cells, as they showed less sensitivity towards the agent,
were treated with 100 μM 5-FU.
Cells were seeded in 60 mm-dishes and 24-well plates
for RNA assays and cell viability assays, respectively. On
the following day, cells were irradiated with 2 Gy using a
137Cs source and treated with 5-FU (Sigma; solved in
DMSO). Controls were treated with the corresponding
volumes of DMSO and sham-irradiated. 24 h after the
first irradiation a second fraction of 2 Gy was applied to
the 5-FU-treated cells followed by incubation for 1 h at
37°C. Cells were harvested by trypsinization and stored
at −20°C until further processing.Cell viability assay (XTT)
In order to determine cell viability of cells treated with
in vitro radiochemotherapy or 5-FU treatment alone, 24-
well plates were used for three biological and two technical
replicates of each condition. XTT-assay was conducted
using 350 μl of Medium and 150 μl of XTT-labeling
mixture. Measurement was performed 24 h after 5-FU
treatment.Colony forming assay
In order to determine the radiation sensitivity of the pri-
mary HNSCC cells, the colony forming assay was per-
formed in 6-well plates (Figure 1c, d). To ensure stable
growth of the primary cells, a feeder layer consisting of
the same HNSCC cells was used. Feeder cells were irra-
diated with 50 Gy in a 60Co source before seeding in the
6-well plates (10,000 cells/well). The following day, fresh
cells for colony formation were plated on the feeder
layer. On the following day the cells were irradiated
using a 137Cs source with 0, 0.5, 1, 2, 3, 5 or 7.5 Gy.
HN1957 colonies were stained with Giemsa six days and
HN2092 colonies 12 days after irradiation. Colonies con-
sisting of at least 50 cells were scored. Each colony
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Figure 1 Sensitivity of primary HNSCC cell cultures to 5-FU treatment and ionizing radiation. Cell viability (XTT-assay) of HN1957 (a) and
HN2092 (b) 48 h after 5-FU treatment relative to DMSO-controls. Each data point represents the mean of three biological replicates. Dashed lines
mark the 5-FU concentrations selected for in vitro radiochemotherapy modeling. Survival curves were generated by colony forming assay for
HN1957 (c) 6 days after irradiation and HN2092 (d) 12 days after irradiation. Error bars represent the standard deviation of three biological replicates.
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peated three times.
RNA extraction
Total RNA was extracted from 300 μl plasma using the
mirVana miRNA Isolation Kit (Ambion) according to
the manufacturer’s protocol with the following modifica-
tion: 1,000 μl of lysis buffer was added to 300 μl of
plasma. 1.04 fmol of synthetic cel-miR-39 (C. elegans)
was added to each plasma sample (300 μl) after the pro-
tein denaturation step to normalize sample-to-sample
variation in RNA recovery. RNA was finally eluted into
50 μl of pre-heated (95°C) nuclease-free water.
RNA from PBMC was extracted with the mirVana
miRNA Isolation Kit (Ambion) according to the manu-
facturer’s protocol. RNA purity was measured by spec-
trophotometry (OD 260/280 ratio) using a Nanodrop
ND-1000 (Thermo Scientific). Ratios were in the range
of 1.89 to 2.09.
Extraction of total RNA from primary HNSCC cells
was performed using the miRNeasy mini kit (Qiagen)according to the manufacturer’s protocol without DNase
digest or small RNA enrichment. OD 260/280 ratios,
measured on a Nanodrop ND-1000 (Thermo Scientific),
were in the range of 1.92 to 2.04. Additionally, RNA
quality was assessed prior to the Agilent microarray ex-
periments using an Agilent 2100 Bioanalyzer (Agilent
Technologies). The computed RNA integrity numbers
(RINs) ranged from 9.3 to 10.0.
MiRNA profiling in patient plasma
TaqMan Array Human MicroRNA A Cards v2.0 (Applied
Biosystems) representing 377 mature human miRNAs
were used to obtain miRNA profiles of the blood
plasma samples. Reverse transcription was performed
using the TaqMan miRNA reverse transcription kit
(Applied Biosystems) in combination with the stem-
loop megaplex primer pool set A v2.1. Because of the
low abundance of circulating miRNA in the starting
material we used a fourfold volume of the reaction mix,
prepared according to the manufacturer’s protocol
adding 12 μl of total plasma RNA.
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of cDNA was used for each array and PCR was carried
out on an Applied Biosystems 7900HT. The reaction
mixtures were incubated at 50°C for 2 min and 95°C
for 10 min, followed by 45 cycles of 95°C for 30 s and
60°C for 1 min. All Ct values were normalized using
the median Ct value of all detectable miRNAs on the
array.
MicroRNA profiling in HNSCC cells
To analyze the effects of in vitro radiochemotherapy on
the cellular miRNA expression levels Sure Print G3 hu-
man 8x60k miRNA microarrays (Agilent Technologies)
were used covering 1205 human miRNAs (Sanger miR-
Base release 16). 100 ng of total RNA was dephosphory-
lated and labeled with cyanine 3-cytidine biphosphate
including a labeling spike-in solution (Agilent Technolo-
gies) to assess the labeling efficiency. After purification of
the labeled RNA, the samples were hybridized on the ar-
rays including a hybridization spike-in solution (Agilent
Technologies) to monitor hybridization efficiency. Arrays
were scanned with a G2505C Sure Scan Microarray Scan-
ner (Agilent Technologies) using Scan Control software.
For data processing the following software was used:
Feature extraction 10.7 (Agilent Technologies) and Gene-
Spring 11.5. MiRNA analysis was conducted with three bio-
logical and two technical replicates for each data point. All
steps were performed according to the manufacturer’s
protocol. The raw data were imported into the R statistical
platform [23]. The total microRNA gene signal (TGS) was
computed by the Agilent Extraction feature. The resulting
signal was normalized to the mean signal of all arrays for
compensation of systematic technical slide-to-slide varia-
tions. A differential expression analysis was performed
using the linear model components implemented in limma
[24] and empirical Bayes methods were applied in order to
attain moderated statistics [25].
Real-time PCR quantification of individual miRNAs
Reverse transcription was performed using the TaqMan
miRNA reverse transcription kit and miRNA-specific
stem-loop primers (Applied Biosystems). Reverse transcrip-
tion was performed on a Cyclone PCR system (Peqlab)
according to the manufacturer’s protocol. For miRNA as-
says in plasma samples 3 μl of cDNA was used for reverse
transcription because of the low RNA content. Real-time
PCR was performed in duplicates and included non-
template negative controls. PCR was performed on aViiA 7
real-time PCR System (Applied Biosystems) following the
manufacturer’s protocol. For plasma samples the miRNA
concentration levels were normalized to the spiked-in
cel-miR-39, for cellular samples the U6 snRNA was used
for normalization. Fold changes were calculated using the
2-ΔΔCt method [26].Statistical analysis
To identify differentially expressed miRNAs in plasma
samples of patients prior to radiotherapy and after the
second fraction of therapeutic irradiation Wilcoxon test
was performed. All miRNAs that were detected in less
than 30% of either control samples or irradiated samples
were excluded from further analysis. Unsupervised hier-
archical clustering was performed using the top distinct-
ive miRNAs applying the parameters maximum distance
and Ward’s method. Fisher’s exact test was applied to
check for significant clustering of samples from patients
prior to treatment and those collected after treatment.
P values < 0.05 were considered statistically significant.
Correlation coefficients for miRNA changes in PBMC
and plasma as well as in arrays and single assays were
calculated using Pearson correlation. All statistical ana-
lyses were performed using The R Project for Statistical
Computing [23].
Results
MiRNA profiling of the plasma samples from 18 head
and neck cancer patients revealed 54 miRNAs with altered
expression levels after treatment (Additional file 2). Un-
supervised hierarchical clustering using the expression
levels of the top six significantly deregulated miRNAs re-
vealed two main clusters. Cluster 1 represents ten samples
collected prior to treatment and two samples collected
after treatment, whereas cluster 2 consists of eight pre-
treatment samples and 16 post-treatment samples. Con-
sequently, the miRNA profiles of these six miRNAs
differentiated significantly (p = 0.012) between samples
collected before therapy and those collected after two
days of treatment (Figure 2). For technical validation of
the array data eight miRNAs (miR-590-5p, miR-574-3p,
miR-425-5p, miR-885-3p, miR-21-5p, miR-28-3p, miR-
195-5p, miR-191-5p) were selected from the top list
of deregulated miRNAs. Additionally, miR-150-5p and
miR-142-3p, both known to play a role in esophageal
carcinoma [27,28], were used for validation. For these
ten miRNAs the differences between the two groups
were validated using single qRT-PCR assays. The correl-
ation coefficients of the normalized Ct values demon-
strated a good correlation between the results of the
TaqMan low density array and the TaqMan single assays
for most of the tested miRNAs (Additional file 3). The
single assays of miR-590-5p and miR-885-3p were below
the detection level in almost all plasma samples and
were consequently excluded from further analyses.
Many plasma miRNAs are known to originate from
peripheral blood mononuclear cells (PBMC) [29]. There-
fore, we measured the expression levels of the candidate
therapy biomarker miRNAs (miR-574-3p, miR-425-5p,
miR-21-5p, miR-28-3p, miR-195-5p, miR-191-5p, miR-
150-5p, miR-142-3p) in PBMC samples obtained from
Figure 2 Unsupervised hierarchical cluster analysis of samples collected before therapy and after two days of treatment. Samples
collected prior to treatment are marked with blue bars, samples collected after two days of treatment (XRT = radiotherapy) are marked with red
bars. Cluster 1 and Cluster 2 indicate the two main clusters emerging from unsupervised cluster analysis using blood plasma concentration levels
of the top six distinctive miRNAs.
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malized Ct values indicated that the changed miRNA
levels after treatment do not originate from PBMC
(Additional file 4).
In order to further investigate whether the plasma
miRNA changes following tumor therapy originate from
the tumor cells we established an in vitro radiochemo-
therapy model using primary HNSCC from two different
patients, HN1957 and HN2092 (Table 2).
For assessment of the sensitivity of the primary tumor
cells to 5-FU and to ionizing radiation dose-response
curves (Figure 1a, b) and survival curves (Figure 1c, d)
were generated, respectively. HN2092 cells showed higher
sensitivity to ionizing radiation but lower sensitivity to
5-FU treatment compared to HN1957 cells. In order to
simulate the treatment of the patient samples in the
present study cells were irradiated with 2 Gy followed by
treatment with 5-FU and on the following day irradiation
with a second 2 Gy fraction. Subsequent measurement of
the cell viability (24 h after 5-FU treatment) showed no
significant effect of 5-FU or irradiation on HN2092 cell
cultures, whereas cell viability of HN1957 cell cultures
was already reduced by 5-FU treatment alone with a sig-
nificant additive effect of irradiation on the cell viability
(Figure 3).
MiRNA profiling using Agilent microarrays in the
sham-irradiated and DMSO-treated control cells com-
pared to cells treated with in vitro radiochemotherapyrevealed several miRNAs that differentiate control cells
and treated cells for HN1957 and HN2092 (Additional
files 5 and 6). We selected three miRNAs (miR-425-5p,
miR-21-5p, miR-106b-5p) that were altered after in vitro
treatment and were also in the top list of therapy-
responsive miRNAs in patient plasma samples after in vivo
tumor therapy. Additionally, miR-93-5p was included as it
shows deregulation after in vitro treatment and in vivo
treatment in most of the patients, although it is not among
the top significant therapy-responsive miRNAs due to the
different directions of regulation (Additional file 7). For
these miRNAs we conducted TaqMan single assays in con-
trol and treated cells to validate the array results. The qRT-
PCR assays confirmed an up-regulation of miR-425-5p
with a p value close to the significance level (p = 0.552) in
HN1957 cell cultures, while for miR-93-5p a significant
down-regulation (p < 0.001) in HN2092 cell cultures be-
came apparent (Table 3). Thus, at least two of the four
treatment-regulated plasma miRNAs are likely to be asso-
ciated with the direct response of tumor cells to treatment.
Discussion
The present study aimed to identify circulating miRNA
markers in the plasma of HNSCC patients that are indi-
cative of the efficacy of radiochemotherapy. Our finding
that a limited panel of deregulated plasma miRNAs dis-
criminates between pre- and post-radiochemotherapy



























Figure 3 Cell viability (XTT-assay) of primary HNSCC cell
cultures. Absorption was measured 24 h after exclusive 5-FU treatment
and 5-FU treatment in combination with 2 x 2 Gy in vitro irradiation
relative to DMSO-controls. Error bars represent the standard deviation of
three biological replicates (*p < 0.05, **p < 0.01).
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responsive biomarkers. Moreover, several candidates
altered after the second fraction of therapeutic irradiation,
such as miR-93-5p, miR-142-3p, miR-106b-5p, miR-191-5p
and miR-21-5p (Additional file 2) have been previously de-
scribed to be induced by ionizing radiation [30].
Although it is known that circulating miRNAs are
present in stable forms, there is still uncertainty about
their transport and cellular origin (reviewed in [31]).
Since circulating miRNAs may originate from blood cells
[29] we tested the hypothesis that the observed therapy-
responsive plasma miRNAs originate from peripheral
blood mononuclear cells (PBMC) of the same patients.
Our analyses of the miRNA profiles of PBMC revealed
no significant correlation between the miRNA expres-
sion in PBMC and plasma in patients before or afterTable 3 MicroRNAs significantly deregulated after radiochem




FC (p value) FC (p valu
miR-425-5p 1.27 (0.004) -
miR-21-5p 1.11 (0.031) -
miR-106b-5p 0.95 (0.042) -
miR-93-5p 0.92 (0.023) 0.96 (0.001
FC = fold change.treatment (Additional file 4). We conclude that the
plasma miRNA changes detected in response to anti-
cancer therapy are most likely not originating from
circulating PBMC.
It has frequently been hypothesized that plasma miR-
NAs originate from tumor cells, either based on active
secretion [32] or in apoptotic bodies released from dead
tumor cells [33]. This is supported by the present study
as several candidates among the top significant plasma
miRNAs that were altered after radiochemotherapy
(Additional file 2) have already been reported to be tumor
markers before. MiR-195-5p, miR-574-3p and miR-28-3p
have been described as being differentially expressed in
esophageal squamous cell carcinoma [34,35]. MiR-191-5p
and miR-21-5p play a role in lung cancer diagnosis and
prognosis [36], while miR-21-5p in plasma also is known
to serve as prognostic marker in esophageal cancer pa-
tients [13]. Taken together, these reports indicate that the
observed changes in plasma miRNAs in our study might
be related to therapy effects on tumor cells.
To further strengthen this hypothesis we investigated
the miRNA expression of primary HNSCC cell cultures
under simulated radiochemotherapeutic treatment
in vitro. The results of the miRNA expression analysis of
this in vitro model further supported the assumption
that the observed plasma miRNA changes are likely to
originate from the tumor cells. We were able to show a
significant deregulation of four plasma miRNAs in
HN1957 cell cultures (miR-425-5p, miR-21-5p, miR-
106b-5p, miR-93-5p) and one plasma miRNA in
HN2092 cell cultures (miR-93-5p) by microarray profil-
ing. The observation that the same miRNAs were altered
in both tumor cells and plasma leads us to conclude that
plasma miRNA changes following radiochemotherapeutic
treatment are the result of miRNA release from damaged
tumor cells. The observed differences in deregulated miR-
NAs between the two cell cultures, however, were not
comparable. The two primary HNSCC cell cultures had
different responses to radiochemotherapeutic treatment.
This may be due to differences in the responsiveness of
the cell cultures. Indeed, the cell viability assay (XTT) ex-
hibited a significant effect 24 h after irradiation and 5-FUotherapeutic treatment in primary HNSCC cell cultures
TaqMan single qRT-PCR assay
HN1957 HN2092




) 1.03 (0.552) 0.84 (0.000)
Summerer et al. Radiation Oncology 2013, 8:296 Page 8 of 9
http://www.ro-journal.com/content/8/1/296treatment on HN1957 cells, but not on HN2092 cells
(Figure 3). This reflects a higher short-term toxicity of
the treatment on HN1957 cell cultures compared to
HN2092 cell cultures, whereas the long-term effect of ir-
radiation is stronger on HN2092 cell cultures as shown in
the colony forming assay (Figure 1c, d). The common de-
regulation of 43 miRNAs in both primary HNSCC cell
cultures (Additional files 5 and 6) suggests a similar
miRNA response to therapeutic treatment independent
from the individual tumor. We also observed differences
in the miRNA response of both HNSCC cell cultures,
which might reflect variations in the individual sensitivity
to radiation and chemotherapeutic treatment (Figure 1).
The major finding of this study, i.e. therapy-related
miRNA expression in the blood plasma is similar to
miRNA changes reported for treated tumor cells, is not
only based on global miRNA array screens but was also
technically validated by qRT-PCR studies of the most
distinctive miRNAs (Table 3). We identified miR-425-5p
(HN1957) and miR-93-5p (HN2092) as top candidates of
commonly deregulated miRNAs in primary HNSCC cell
cultures and blood plasma of HNSCC patients.
In conclusion, the present study compared miRNA
data from blood plasma of radiochemotherapy-treated
HNSCC patients and from an in vitro model of primary
tumor cell radiochemotherapy. This comparison sheds
light on the origin and potential use of circulating miR-
NAs in the blood plasma of HNSCC patients as therapy-
responsive biomarkers. We will further integrate these
therapy-responsive plasma miRNAs with clinical data of
the patients (e.g. overall survival) and seek for independent
validation in another patient cohort in order to evaluate
their potential for prognostic use. The established HNSCC
cell culture model further allows us to investigate the mo-
lecular interactome of the deregulated miRNA candidates
by adding mRNA expression data and subsequent integra-
tive data analysis.
The current study strongly suggests that alterations of
miRNAs following radiochemotherapy in the blood plasma
are associated with the tumor response to therapy and
therefore might represent novel biomarkers for therapy
monitoring.Additional files
Additional file 1: Immunohistochemical cytokeratin-staining of
primary HNSCC cultures.
Additional file 2: Therapy-responsive microRNAs in plasma samples
of 18 head and neck cancer patients.
Additional file 3: Correlation coefficients of normalized Ct values
(ΔCt) of plasma miRNAs analyzed with arrays and single assays.
Additional file 4: Correlation coefficients of normalized Ct values
(ΔCt) of miRNAs analyzed with TaqMan single assays in PBMC and
plasma.Additional file 5: Significantly deregulated microRNAs in HN1957
primary cell cultures after in vitro radiochemotherapy.
Additional file 6: Significantly deregulated microRNAs in HN2092
primary cell cultures after in vitro radiochemotherapy.
Additional file 7: Expression levels of miR-93-5p in plasma of 18
head and neck cancer patients prior and post treatment.
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